Literature DB >> 11739516

Immune elimination of Leishmania major in mice: implications for immune memory, vaccination, and reactivation disease.

J E Uzonna1, G Wei, D Yurkowski, P Bretscher.   

Abstract

Infection of susceptible BALB/c mice with a large, moderate, or low number of Leishmania major parasites respectively results in progressive disease, the formation of substantial but stable lesions, denoted as borderline disease, and the absence of a visible lesion. Infection with a low number of parasites results over the long term in either subclinical infections or an asymptomatic state. Subclinical mice produce a predominant Th1 response and are resistant to challenge, in contrast to their asymptomatic counterparts. Statistical and other evidence suggest that the asymptomatic state can arise from a subclinical state following parasite clearance, with consequent loss of resistance. Cell transfer studies demonstrate unequivocally that immune cells from subclinical mice can protect naive mice against a pathogenic challenge and can clear the parasite, leaving the mice susceptible to a rechallenge infection. This susceptibility is associated with the disappearance of both parasite-specific effector and memory T cells from secondary lymphoid organs. These findings have implications for vaccination, maintenance of memory, and prevention of reactivation disease.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11739516     DOI: 10.4049/jimmunol.167.12.6967

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  72 in total

1.  Persistence and function of central and effector memory CD4+ T cells following infection with a gastrointestinal helminth.

Authors:  Colby Zaph; Kathryn A Rook; Michael Goldschmidt; Markus Mohrs; Phillip Scott; David Artis
Journal:  J Immunol       Date:  2006-07-01       Impact factor: 5.422

2.  Immunity and protection, the unfolding of a tale.

Authors:  Maurizio Zanetti
Journal:  Immunol Res       Date:  2007       Impact factor: 2.829

3.  Immunization with persistent attenuated Delta lpg2 Leishmania major parasites requires adjuvant to provide protective immunity in C57BL/6 mice.

Authors:  Chahnaz Kébaïer; Jude E Uzonna; Stephen M Beverley; Phillip Scott
Journal:  Infect Immun       Date:  2006-01       Impact factor: 3.441

Review 4.  Persistent parasites and immunologic memory in cutaneous leishmaniasis: implications for vaccine designs and vaccination strategies.

Authors:  Ifeoma Okwor; Jude Uzonna
Journal:  Immunol Res       Date:  2008       Impact factor: 2.829

5.  Early induction of interleukin-10 limits antigen-specific CD4⁺ T cell expansion, function, and secondary recall responses during persistent phagosomal infection.

Authors:  Abinav Kumar Singh; Nagaraja R Thirumalapura
Journal:  Infect Immun       Date:  2014-07-14       Impact factor: 3.441

6.  Dissecting the requirements for maintenance of the CMV-specific memory T-cell pool.

Authors:  Andrea I Loewendorf; Ramon Arens; Jared F Purton; Charles D Surh; Chris A Benedict
Journal:  Viral Immunol       Date:  2011-07-01       Impact factor: 2.257

7.  Early effector cells survive the contraction phase in malaria infection and generate both central and effector memory T cells.

Authors:  Michael M Opata; Victor H Carpio; Samad A Ibitokou; Brian E Dillon; Joshua M Obiero; Robin Stephens
Journal:  J Immunol       Date:  2015-04-24       Impact factor: 5.422

8.  Coinjection with CpG-containing immunostimulatory oligodeoxynucleotides reduces the pathogenicity of a live vaccine against cutaneous Leishmaniasis but maintains its potency and durability.

Authors:  Susana Mendez; Khaled Tabbara; Yasmine Belkaid; Sylvie Bertholet; Daniela Verthelyi; Dennis Klinman; Robert A Seder; David L Sacks
Journal:  Infect Immun       Date:  2003-09       Impact factor: 3.441

9.  BALB/c mice vaccinated with Leishmania major ribosomal proteins extracts combined with CpG oligodeoxynucleotides become resistant to disease caused by a secondary parasite challenge.

Authors:  Laura Ramírez; Salvador Iborra; Jimena Cortés; Pedro Bonay; Carlos Alonso; Manoel Barral-Netto; Manuel Soto
Journal:  J Biomed Biotechnol       Date:  2010-01-26

10.  Leishmaniasis Vaccine: Where are We Today?

Authors:  Lukasz Kedzierski
Journal:  J Glob Infect Dis       Date:  2010-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.